Companies › Lineage Cell Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LCTOPC1 Oligodendrocyte progenitor cell therapy for spinal cord injury repair | – | Phase 1 | Spinal Cord Injury Cervical | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06841770 | LCTOPC1 | Phase 1 | Spinal Cord Injury Cervical | Neurology | Aug 2027 |
Cash and short-term investments of $51m on 2026-06-30; operating cash outflow about $31m a year; runway about 20 months at that burn, to Feb 2028
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.